- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 72 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| 25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 428 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health announces distribution agreement with Virax Biolabs | 3 | Seeking Alpha | ||
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 324 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 17.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.12.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.12.24 | Virax Biolabs: Interview With COO Nigel McCracken About The Diagnostics And Detection Company | 1 | pulse2.com | ||
| 20.11.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.10.24 | Virax Biolabs announces 2024 annual meeting | 2 | Investing.com | ||
| 31.10.24 | Virax Biolabs kündigt Jahreshauptversammlung 2024 an | - | Investing.com Deutsch | ||
| 31.10.24 | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,20 | +0,35 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| EVOTEC | 5,905 | -3,59 % | Kursraketen und Übernahmefantasie! Steyr Motors, Evotec und Defence Therapeutics! | Steyr Motors reitet jetzt nicht nur die Rüstungs-, sondern auch die Übernahmewelle. Nach der Kooperationsmeldung mit einer Rheinmetall-Tochter ist der Nischenwert zum Shootingstar geworden. Allerdings... ► Artikel lesen | |
| BAVARIAN NORDIC | 19,970 | -0,45 % | Bavarian Nordic Aktie: Stabiler Markteintritt erwartet | Bavarian Nordic erzielte im Geschäftsjahr 2024 einen Umsatz von 5.716 Millionen DKK, was im Rahmen der zuvor kommunizierten Prognose von 5.400 bis 5.800 Millionen DKK liegt. Das Betriebsergebnis (EBITDA)... ► Artikel lesen | |
| ASEP MEDICAL | 0,050 | +23,76 % | ASEP Medical Holdings Inc: ASEP to issue 26.87M shares for debt of $1.34M | ||
| EMERGENT BIOSOLUTIONS | 4,800 | +0,82 % | Emergent BioSolutions Aktie: Indien undurchdringlich? | Der Biotech-Konzern verkauft seine Baltimore-Anlage für 36,5 Millionen Dollar an das indische Unternehmen, während die Aktie weiter unter Druck gerät. Emergent BioSolutions hat am 10. März 2025 seine... ► Artikel lesen | |
| GINKGO BIOWORKS | 5,600 | +0,90 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results | Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an... ► Artikel lesen | |
| GENPREX | 1,820 | -100,00 % | Genprex, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| PALISADE BIO | 0,666 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 | Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2024ISIN NameUS23636BAV18 DANSKE... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 5,500 | +0,46 % | SIGA Technologies - Entering a crucial period for business outlook | SIGA Technologies reported another year of top-line growth in FY24, with performance weighted to Q4, driven by material TPOXX deliveries to both domestic and international markets. Product revenue grew... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs CEO David Dodd erwirbt Stammaktien im Wert von 10.800 US-Dollar | ||
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| ANNOVIS BIO | 1,456 | -0,41 % | Annovis Bio Inc.: Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE | MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 2,420 | -18,24 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates | Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational... ► Artikel lesen | |
| HUMACYTE | 1,450 | 0,00 % | Humacyte, Inc: Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update | - Received U.S. Food and Drug Administration (FDA) approval of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first... ► Artikel lesen |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.
